• Benzyl Alcohol in Ang II Vascular and Renal Injury

  2026-10-09

  A 2025 study identified benzyl alcohol as a metabolomics-linked candidate for reducing Angiotensin II-associated vascular remodeling and renal injury in mice. Its findings support a preclinical connection between metabolite discovery, vascular reactivity, blood pressure, and kidney biomarkers, while remaining preliminary for pediatric hypertension and human treatment.

• MALAT1, TDP-43, and Nuclear RNA Regulation

  2026-10-09

  A 2025 Journal of Biological Chemistry study shows that changing MALAT1 levels affects cell viability and redistributes TDP-43 binding across mRNA targets in human cell models. The work links a highly expressed nuclear long noncoding RNA to RNA-binding-protein function while emphasizing that MALAT1 effects can differ between baseline survival and toxin-stressed conditions.

• 10058-F4: A c-Myc–TERT Evidence Map

  2026-10-08

  10058-F4 is a c-Myc-Max dimerization inhibitor used to examine oncogenic transcription, apoptosis, and lineage-specific responses. This evidence-focused guide connects its reported cancer-model effects with new findings on APEX2, TERT expression, and DNA-repair-associated transcription—while clearly separating established findings from testable interpretation.

• AKTIP in Fibrolamellar Carcinoma: What the Study Shows

  2026-10-08

  A 2025 study integrated WGCNA, machine learning, public transcriptomic datasets, and computational drug-response analyses to identify AKTIP as a candidate biomarker for fibrolamellar carcinoma. Its findings are promising for hypothesis generation, but prospective clinical validation and biological experiments are still needed before AKTIP can be considered a clinically established diagnostic or therapeutic target.

• NSP15 Natural-Product Screening: What the Study Shows

  2026-10-07

  A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 NSP15 endoribonuclease and identified thymopentin and oleuropein as the leading computational candidates. Molecular-dynamics analyses supported persistent protein–ligand interactions, but the findings remain hypothesis-generating because biochemical, cellular, infection-model, and clinical validation were not reported.

• MEK/ERK, c-Myc, and TERT in Human Stem Cells

  2026-10-07

  A 2024 bioRxiv preprint identifies a regulatory connection between MEK/ERK signaling, c-Myc:MAX activity, and polycomb-mediated repression of TERT in human embryonic stem cells. Its findings suggest that TERT transcription is controlled not only by kinase signaling but also by chromatin-state changes at the TERT promoter, while highlighting important limits on extrapolating these results to cancer models.

• SFI, SRC/PI3K/AKT, and Glioma Evidence

  2026-10-06

  A 2024 Journal of Ethnopharmacology study combined network pharmacology with cellular and animal experiments to investigate how Shenqi Fuzheng injection affects glioma proliferation and migration. Its evidence implicates the SRC/PI3K/AKT pathway, while also showing why pathway predictions require validation across models before supporting broader therapeutic or anti-angiogenic conclusions.

• Angiotensin II as a Systems-Level Hypertension Probe

  2026-10-05

  Angiotensin II is more than a vasoconstrictor: it is a useful systems-level probe for connecting receptor signaling with endothelial dysfunction and cardiovascular remodeling. This article interprets the peptide through the endothelial Sp1/Sp3 findings reported in Nature Communications and defines evidence-aware research applications without presenting procedural protocols.

• 10058-F4: c-Myc-Max Inhibitor Evidence

  2026-10-05

  10058-F4 is a c-Myc-Max dimerization inhibitor used to study c-Myc transcription factor inhibition. Vendor-described cancer models report apoptosis- and differentiation-associated effects, while a 2024 hESC preprint links c-Myc:MAX disruption to TERT repression and polycomb-associated chromatin changes.

• Sex Differences in Angiotensin II Hypertension

  2026-10-04

  The reference study showed that chronic Angiotensin II exposure produced a much larger blood-pressure increase in conscious male mice than in female mice. Gonadectomy reversed much of this pattern, while telemetry, baroreflex testing, and autonomic blockade linked the sex difference to altered reflex and sympathetic regulation rather than to baseline blood pressure alone.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-10-03

  A 2025 study found that several naturally occurring angiotensin fragments increased the binding of SARS-CoV-2 spike protein to host-cell receptors, with particularly strong effects observed for shorter N-terminal deletion products and angiotensin IV. The work introduces a sequence-sensitive connection between renin-angiotensin system biology and viral receptor-binding research, while remaining limited to biochemical binding evidence rather than infection or clinical outcomes.

• Talabostat Mesylate: Applied Research Workflows

  2026-10-02

  Talabostat mesylate enables controlled interrogation of DPP4 and FAP biology across enzyme, tumor-cell, and immune-response assays. This workflow-focused guide connects target engagement with FAP-positive controls, cytokine measurements, and the N-degron findings of a 2024 protein-stability study—while clearly separating validated evidence from exploratory extensions.

• P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL

  2026-10-01

  A 2025 study links P2RX1 activation to calcium/CaMKII-dependent inhibition of PI3K/Akt signaling and mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. Its findings suggest that P2RX1 may influence both prognosis and tyrosine kinase inhibitor responsiveness, while also defining a multi-readout framework for studying leukemia cell death.

• PDE4B in Angiotensin II–Induced Endothelial Dysfunction

  2026-10-01

  The reference study identifies PDE4B as a stress-associated mediator of Angiotensin II–induced endothelial injury in HUVECs and links its suppression to activation of the AMPK/Sirt1/Nrf2/ARE antioxidant pathway. Its combined viability, apoptosis, angiogenesis, endoplasmic-reticulum-stress, and mitochondrial assays provide a mechanistic framework for interpreting endothelial dysfunction in hypertension models.

• ALC-0159 for mRNA Lipid Nanoparticle Workflows

  2026-09-30

  ALC-0159 is a PEG-conjugated lipid excipient for building and refining mRNA lipid nanoparticles, including formulations used in cancer-immunotherapy research. This practical guide separates formulation variables from biological effects and provides executable starting conditions, assay choices, and troubleshooting checkpoints.

7885 records 1/526 page Next 12345 下5页 Last page